News und Analysen
![3 AI Stocks not Named Nvidia That Have Doubled This Year: https://g.foolcdn.com/editorial/images/736732/two-people-working-on-their-computers-in-a-shared-space.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWszYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d4d24489c8990166012e00435a183a03d488efee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-people-working-on-their-computers-in-a-shared-space.jpg?locale=de)
3 AI Stocks not Named Nvidia That Have Doubled This Year
Nvidia attracted plenty of investor excitement this year thanks to the increased hype surrounding artificial intelligence (AI). That excitement was enough to help it exceed a $1 trillion market cap
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=de)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Alleged Industrial Espionage Makes an Interesting Story: https://g.foolcdn.com/editorial/images/736757/mfm_20230615.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzQzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7c57c1ee9853db09bec0132f800623bcc1191c1c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/mfm_20230615.jpg?locale=de)
Alleged Industrial Espionage Makes an Interesting Story
In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:
Motley Fool host Ricky Mulvey and analyst Kirsten Guerra take a look at Vertex Pharmaceuticals and its role at
![Why Shares of Patterson Companies Shot Up Wednesday: https://g.foolcdn.com/editorial/images/737118/veterinary-medicine_-vet-holds-cat.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNUEzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e92b5d668b3f8a89ea9fa01a8dcb5e696bc1f425/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/veterinary-medicine_-vet-holds-cat.jpg?locale=de)
Why Shares of Patterson Companies Shot Up Wednesday
Shares of Patterson Companies (NASDAQ: PDCO) were up 14.7% Wednesday afternoon after rising as much as 28.3%, hitting a 52-week high of $32.82. The healthcare company, which makes products and
![Why AI Is Revolutionizing the Consumer Goods Industry, and How to Profit From It: https://g.foolcdn.com/editorial/images/737008/thinking-robot-flipped.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGMzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fd8f234bc0bfc2ac4a1fae46f49d693629d84fe1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/thinking-robot-flipped.jpg?locale=de)
Why AI Is Revolutionizing the Consumer Goods Industry, and How to Profit From It
There are many ways to invest in the ongoing artificial intelligence (AI) boom. You don't even have to focus on Silicon Valley and friends. The AI tools tech giants provide can have game-changing
![Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?: https://g.foolcdn.com/editorial/images/736669/investor-considers-papers-at-a-cafe.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBdzAzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6eb2c0d4e6abadab656d47efd46ffc1f341449ee/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-considers-papers-at-a-cafe.jpg?locale=de)
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?
Over the last couple of weeks, Cathie Wood's ARK Innovation ETF has been busy buying shares of gene-editing biotech Intellia Therapeutics (NASDAQ: NTLA). She's also been selling some shares of
![History Suggests This S&P 500 Dividend Stock Is Perfect to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/733946/veterinarian-works-with-dog.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeE0zYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d36c5845434749166d5524478e699c4d4f3d0282/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/veterinarian-works-with-dog.jpg?locale=de)
History Suggests This S&P 500 Dividend Stock Is Perfect to Buy and Hold Forever
Over time, stocks with growing dividends and high returns on invested capital (ROICs) have tended to outperform their peers. By highlighting these qualities -- plus a payout ratio below 50% --
![Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030: https://g.foolcdn.com/editorial/images/736672/two-investors-look-at-figures.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFUyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6c3b65fe46fb2d76e9b4e7c7d7041b23f7e27874/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-investors-look-at-figures.jpg?locale=de)
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030
Despite its shares being down almost 10% over the past five years, there's reason to believe that CRISPR Therapeutics (NASDAQ: CRSP) is finally about to soar. With its first medicines approaching
![This Healthcare Stock Is Sending More Cash to Its Shareholders: Should You Buy It?: https://g.foolcdn.com/editorial/images/736648/a-doctor-and-patient-at-an-appointment.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGcyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a222f8683ff7bb04c4c7c479d77c4ca4f7c5afc8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-and-patient-at-an-appointment.jpg?locale=de)
This Healthcare Stock Is Sending More Cash to Its Shareholders: Should You Buy It?
The primary objective of dividend growth investing is to build an investment portfolio that can provide an investor with reliable and growing streams of passive income. The dividends can be used
![1 Growth Stock Down 66% to Buy Right Now: https://g.foolcdn.com/editorial/images/736684/dog-with-owners-looking-at-laptop.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMDAyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e756122702dfbeead72b429bc2c0ac32432edfa3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/dog-with-owners-looking-at-laptop.jpg?locale=de)
1 Growth Stock Down 66% to Buy Right Now
Ideally, growth stocks are supposed to, well, grow. But that doesn't always happen.
Sometimes, even the best stocks experience steep downturns. The good news is that these sell-offs present great
![Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN042Vmc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae05d9a008178586e36a804ddc8db7301200475e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/5009664_Horizon_Logo_Full-Color_CMYK_M01_-281-29.jpg?locale=de)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
![Is CRISPR Therapeutics Stock a Buy Now?: https://g.foolcdn.com/editorial/images/736895/gettyimages-1096502340.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMU0yYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--76070af6088685011d8669b9d452c64cbce85e31/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1096502340.jpg?locale=de)
Is CRISPR Therapeutics Stock a Buy Now?
An important moment may be only a few months away for CRISPR Therapeutics (NASDAQ: CRSP). I'm talking about the potential approval of its very first product. The U.S. Food and Drug Administration
![Why Shares of Vera Therapeutics Jumped Tuesday: https://g.foolcdn.com/editorial/images/736985/radiologist-of-oncology-institute-is-examing-mri-scans.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWsyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cc35a5f92766b15851792a411ac4d6a1882cab5a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/radiologist-of-oncology-institute-is-examing-mri-scans.jpg?locale=de)
Why Shares of Vera Therapeutics Jumped Tuesday
Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one
![Why Quotient Technology Stock Was Up on Tuesday: https://g.foolcdn.com/editorial/images/736914/online-shopping-with-credit-card-at-home.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlUxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3891a7dcbc6a61976d81603ebfb94c6b04d7ad19/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/online-shopping-with-credit-card-at-home.jpg?locale=de)
Why Quotient Technology Stock Was Up on Tuesday
Quotient Technology (NYSE: QUOT) shareholders had a great to start to the trading week. The digital promotions and media tech specialist's stock jumped 16% in early trading, compared to a nearly 1%
![Better Buy: AT&T vs. Amazon: https://g.foolcdn.com/editorial/images/736707/family-piggy-bank.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmMxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fd2f3f511b86be1494aa73062a2ba43f7aa5f88c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/family-piggy-bank.jpg?locale=de)
Better Buy: AT&T vs. Amazon
AT&T (NYSE: T) and Amazon (NASDAQ: AMZN) are both often considered stable long-term investments. AT&T is one of the largest telecom companies in the United States, and it has paid continuous
![After Blasting Off 881% in 1 Year, Is Viking Therapeutics Still a Good Buy?: https://g.foolcdn.com/editorial/images/736473/scientists-lab-testing-vaccine-development1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzgxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e49a6513ac7e2df4650269e0b362f3d37c183027/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-lab-testing-vaccine-development1.jpg?locale=de)
After Blasting Off 881% in 1 Year, Is Viking Therapeutics Still a Good Buy?
Viking Therapeutics (NASDAQ: VKTX) is up 881% in the last 12 months thanks to its ongoing development of a pair of therapies to treat obesity and metabolic disorders like diabetes. As you may have
![EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBMUT09IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--5ccaaee20e4dd47dccd2b888e74ce998199f16f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Evotec_high_res_logo_-28blue_and_grey-29.jpg?locale=de)
EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items
![Where Will Axsome Therapeutics Be in 3 Years?: https://g.foolcdn.com/editorial/images/736806/gettyimages-1147525564.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeTgxYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2b4df45a23f85f0193aef1e701f5bb98e90521f5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-1147525564.jpg?locale=de)
Where Will Axsome Therapeutics Be in 3 Years?
Last year was a big one for Axsome Therapeutics (NASDAQ: AXSM). The biotech company specialized in central nervous system conditions launched its first two products and saw its share price increase
![Best Dividend Stock to Buy: AT&T vs. Deere: https://g.foolcdn.com/editorial/images/736838/untitled-design-32.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzAwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--635939a584b2637d085138d835530dc9a8518442/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/untitled-design-32.png?locale=de)
Best Dividend Stock to Buy: AT&T vs. Deere
Fool.com contributor and finance professor Parkev Tatevosian compares AT&T (NYSE: T) and Deere (NYSE: DE) to determine which is the better dividend stock to buy.
*Stock prices used were the
![Illumina's CEO Was Just Ousted: Should Investors Buy In Now or Steer Clear?: https://g.foolcdn.com/editorial/images/736470/3-worried-investors-talk-at-a-table.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmMwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ec1b806b8f3c8ba959d0331d8584e9eda5ea8ff0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/3-worried-investors-talk-at-a-table.jpg?locale=de)
Illumina's CEO Was Just Ousted: Should Investors Buy In Now or Steer Clear?
On June 11, the gene sequencing giant Illumina (NASDAQ: ILMN) announced that its CEO, Francis deSouza, resigned after a tenure of roughly 10 years and that the company would start looking for a
![What Do Bears Know About Novavax That Bulls Don't?: https://g.foolcdn.com/editorial/images/736798/gettyimages-healthcare-worker-prepares-vaccine-dose.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNncwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5967784116787be0d949edaeb18056bc7b9d9d25/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/gettyimages-healthcare-worker-prepares-vaccine-dose.jpg?locale=de)
What Do Bears Know About Novavax That Bulls Don't?
Novavax (NASDAQ: NVAX) soared early in the coronavirus vaccine race. The stock climbed more than 2,700% in 2020.
But as the biotech company fell behind in the race, so did its shares. Novavax
![If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position: https://g.foolcdn.com/editorial/images/736546/healthcare-lab-treatment-research-scientist-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjAwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--565224ccb7a802ee4bee0b2797f05b348dec5bd0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare-lab-treatment-research-scientist-1.jpg?locale=de)
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position
Nano-X Imaging (NASDAQ: NNOX), DermTech (NASDAQ: DMTK), and Viking Therapeutics (NASDAQ: VKTX) are healthcare growth stocks with plenty of potential, little revenue, and a boatload of risk.
Share
![Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions: https://g.foolcdn.com/editorial/images/736519/a-customer-shops-at-a-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMDgwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae19a7f2340b90932e7519809b00477f7de74c07/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-customer-shops-at-a-pharmacy.jpg?locale=de)
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to
![Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.: https://g.foolcdn.com/editorial/images/736480/scientists-lab-testing-blood-draw1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMUkwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d4e787166626a1144346a9a56a6ec81a423f00c2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientists-lab-testing-blood-draw1.jpg?locale=de)
Intellia Therapeutics Stock Could Roar in the Next Bull Market. Here's Why.
Even after rising 30% so far this year, shares of Intellia Therapeutics (NASDAQ: NTLA) could easily experience another leg up if there's a bull market in the latter half of 2023. With positive
![2 Promising Stocks That Are Screaming Buys in June: https://g.foolcdn.com/editorial/images/736431/a-person-looking-at-a-computer.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWMwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d63465ebf7b768e4e002f3f66078fc50ce72273c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-person-looking-at-a-computer.jpg?locale=de)
2 Promising Stocks That Are Screaming Buys in June
While 2022 was disastrous for much of the market, 2023 is shaping up to be much better, with the S&P 500 already up nearly 15% so far this year. Long-term investors understand that these ups and